Question 1

What does the research say about omega-3 fish oil and heart health?

Accepted Answer

Evidence is dose- and context-dependent. The REDUCE-IT trial (n=8,179, PMID: 30415628) found that prescription-dose icosapentaenoic acid (4 g/day) reduced major cardiovascular events by 25% over 4.9 years in a high-risk population. However, the VITAL trial (n=25,871, PMID: 30415630) found that 1 g/day of conventional fish oil did not significantly reduce the primary CVD composite endpoint, though secondary analyses showed a significant reduction in myocardial infarction. Meta-analyses of standard fish oil supplements show consistent triglyceride reduction but inconsistent benefit for hard cardiovascular outcomes.

Question 2

What dosage ranges have been studied for omega-3 fish oil?

Accepted Answer

Trials have used a wide range. For triglyceride reduction, effective doses start at approximately 2 g/day combined EPA+DHA. The REDUCE-IT trial used 4 g/day pure EPA (icosapentaenoic acid). Most intervention trials for general cardiovascular and anti-inflammatory effects use 1–3 g/day combined EPA+DHA. For rheumatoid arthritis, benefit has been observed at ≥2.7 g/day EPA+DHA from 12 weeks. Product labels can be misleading — 1,000 mg fish oil capsules often contain only 300–500 mg combined EPA+DHA; checking the supplement facts panel for the EPA+DHA content is essential.

Question 3

What side effects have been reported in trials of omega-3 fish oil?

Accepted Answer

Gastrointestinal side effects — including fish burps (eructation), nausea, and loose stools — are the most commonly reported adverse events at doses above 3 g/day. Enteric-coated formulations reduce fishy aftertaste in comparative studies. At pharmacological doses (≥3 g/day), fish oil has a measurable antiplatelet effect, extending bleeding time; the European Food Safety Authority notes that doses up to 5 g/day are safe for the general population. Rare cases of atrial fibrillation were reported in the ASCEND and VITAL-Rhythm substudies at high doses.

Question 4

Is there evidence for omega-3 supplementation during pregnancy?

Accepted Answer

DHA is a structural component of fetal brain and retinal development. Observational studies consistently associate higher maternal DHA status with improved neurodevelopmental outcomes. The CHILD study and several RCTs have investigated EPA+DHA supplementation in pregnancy; NICE recommends pregnant women eat 1–2 portions of oily fish per week as the preferred route to EPA+DHA. Trials report that supplementation with 200–1,000 mg DHA/day during pregnancy is well-tolerated; the European Commission has established an AI of 200 mg/day DHA during pregnancy and lactation.

Question 5

What forms of omega-3 have the strongest evidence base?

Accepted Answer

Triglyceride (TG) form omega-3s demonstrate 25–73% higher bioavailability than ethyl ester (EE) form in pharmacokinetic studies, particularly when taken with a high-fat meal. Re-esterified triglyceride (rTG) form closely matches the natural oil found in fish. Most consumer products are ethyl esters. Krill oil contains omega-3s in phospholipid form, which some studies suggest improves brain uptake, though head-to-head clinical trial evidence versus fish oil TG form is limited. Algal oil (EPA+DHA from microalgae) is the evidence-based alternative for those avoiding fish.

Question 6

What do NHS and EFSA say about omega-3 fish oil?

Accepted Answer

The NHS recommends at least two portions of fish per week, one of which should be oily fish, as the preferred dietary route to EPA+DHA. The NHS advises those who do not eat fish can take omega-3 supplements. EFSA has authorised health claims for EPA and DHA combined: maintenance of normal blood triglyceride levels (at 2 g/day), normal blood pressure (at 3 g/day), normal cardiac function (at 250 mg/day), and maintenance of normal brain function and vision (at 250 mg DHA/day).

Question 7

What does the research say about omega-3 and inflammation?

Accepted Answer

Mechanistic and clinical evidence shows that EPA and DHA compete with arachidonic acid for cyclooxygenase and lipoxygenase enzymes, reducing the synthesis of pro-inflammatory eicosanoids (prostaglandin E2, leukotriene B4) and promoting pro-resolving mediators (resolvins, protectins). Meta-analyses show consistent reductions in C-reactive protein, IL-6, and TNF-α with supplementation in populations with elevated baseline inflammation. A Cochrane-level review by Calder (2017, PMID: 28838588) concluded EPA and DHA have anti-inflammatory properties, with effects proportional to baseline inflammatory status.

Grade	Health Outcome	Studies	Participants	Effect
A	Triglyceride Reduction21 studies	21	1,516	Meta-analysis of 21 RCTs confirms dose-dependent reduction in serum triglycerides; at 2 g/day EPA+DHA combined, mean triglyceride reduction is approximately −15% to −20%; prescription-dose icosapentaenoic acid (4 g/day) reduces triglycerides by up to 45% in hypertriglyceridaemia
B	Cardiovascular Events13 studies	13	127,477	REDUCE-IT trial (n=8,179, icosapentaenoic acid 4 g/day, 4.9 years) found a 25% relative risk reduction in major adverse cardiovascular events; however, meta-analyses of conventional fish oil supplements (1–2 g/day) show inconsistent results — ORIGIN and VITAL trials found no significant reduction in CVD events
B	Systemic Inflammation18 studies	18	1,522	Meta-analyses show consistent reductions in inflammatory biomarkers (CRP, IL-6, TNF-α) with EPA+DHA supplementation in adults with elevated baseline inflammation; EPA and DHA compete with arachidonic acid for COX/LOX enzymes, reducing pro-inflammatory eicosanoid production
B	Rheumatoid Arthritis & Joint Pain17 studies	17	823	Meta-analysis of 17 RCTs in rheumatoid arthritis found EPA+DHA supplementation significantly reduced joint pain intensity, morning stiffness, and NSAID use; effects observed from 12 weeks and at doses ≥2.7 g/day EPA+DHA
C	Cognitive Function (Healthy Adults)10 studies	10	3,204	Meta-analyses of omega-3 supplementation in healthy adults without cognitive impairment show inconsistent results; benefits for episodic memory and processing speed are modest and primarily observed in older adults or those with DHA insufficiency at baseline

What does the research say about Omega-3 Fish Oil?

How much Omega-3 Fish Oil is used in clinical trials?

What side effects have been reported?

Which form of Omega-3 Fish Oil has the strongest evidence base?

Omega-3 Fish Oil

The Evidence

Omega-3 Fatty Acids — Health Professional Fact Sheet

The Relationship of Omega-3 Fatty Acids with Dementia and Cognitive Decline: Evidence from Prospective Cohort Studies of Supplementation, Dietary Intake, and Blood Markers

Effects of long-chain omega-3 polyunsaturated fatty acids on reducing anxiety and/or depression in adults: A systematic review and meta-analysis of randomised controlled trials

Efficacy of the omega-3 fatty acids supplementation on inflammatory biomarkers: An umbrella meta-analysis

Effect of Long-Term Marine Omega-3 Fatty Acids Supplementation on the Risk of Atrial Fibrillation in Randomized Controlled Trials of Cardiovascular Outcomes: A Systematic Review and Meta-Analysis

Effect of omega-3 fatty acids on cardiovascular outcomes: A systematic review and meta-analysis

Fish oil supplements, oxidative status, and compliance behaviour: Regulatory challenges and opportunities

Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial

Marine Omega-3 Supplementation and Cardiovascular Disease: An Updated Meta-Analysis of 13 Randomized Controlled Trials Involving 127 477 Participants

Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association

Efficacy of omega-3 PUFAs in depression: A meta-analysis

Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer

Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia

Oxidation levels of North American over-the-counter n-3 (omega-3) supplements and the influence of supplement formulation and delivery form on evaluating oxidative safety

Scientific Opinion on the Tolerable Upper Intake Level of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA)

Evidence Database

Supplier Directory

Myprotein

Bulk

Amazon UK

Holland & Barrett

Thorne

Cost Comparison

General Information

Dosage (Evidence-Reported)

Safety Notes

Key Benefits

Quick Facts

Frequently Asked Questions